CL2010000395A1 - Composicion farmaceutica que comprende dabigatran, inhibidor directo de la trombina y uno o mas inhibidores de plaquetas seleccionado entre clopidogrel y ticlopidina; y su uso para tratar enfermedades tales como trombosis venosa profunda y embolia pulmonar, entre otros eventos troboticos.8divisional de la solictud 687-06) - Google Patents
Composicion farmaceutica que comprende dabigatran, inhibidor directo de la trombina y uno o mas inhibidores de plaquetas seleccionado entre clopidogrel y ticlopidina; y su uso para tratar enfermedades tales como trombosis venosa profunda y embolia pulmonar, entre otros eventos troboticos.8divisional de la solictud 687-06)Info
- Publication number
- CL2010000395A1 CL2010000395A1 CL2010000395A CL2010000395A CL2010000395A1 CL 2010000395 A1 CL2010000395 A1 CL 2010000395A1 CL 2010000395 A CL2010000395 A CL 2010000395A CL 2010000395 A CL2010000395 A CL 2010000395A CL 2010000395 A1 CL2010000395 A1 CL 2010000395A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- events
- trobotic
- dabigatran
- ticlopidine
- Prior art date
Links
- 206010051055 Deep vein thrombosis Diseases 0.000 title abstract 2
- 208000010378 Pulmonary Embolism Diseases 0.000 title abstract 2
- 206010047249 Venous thrombosis Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 title abstract 2
- 239000003868 thrombin inhibitor Substances 0.000 title abstract 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 title 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 title 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 title 1
- 229960003009 clopidogrel Drugs 0.000 title 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 title 1
- 229960003850 dabigatran Drugs 0.000 title 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 title 1
- 229960005001 ticlopidine Drugs 0.000 title 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 abstract 1
- 229940122388 Thrombin inhibitor Drugs 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05006711 | 2005-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2010000395A1 true CL2010000395A1 (es) | 2010-08-20 |
Family
ID=36423564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2010000395A CL2010000395A1 (es) | 2005-03-29 | 2010-04-21 | Composicion farmaceutica que comprende dabigatran, inhibidor directo de la trombina y uno o mas inhibidores de plaquetas seleccionado entre clopidogrel y ticlopidina; y su uso para tratar enfermedades tales como trombosis venosa profunda y embolia pulmonar, entre otros eventos troboticos.8divisional de la solictud 687-06) |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20060222640A1 (OSRAM) |
| EP (1) | EP1885354A2 (OSRAM) |
| JP (1) | JP2008534552A (OSRAM) |
| KR (1) | KR20070116936A (OSRAM) |
| CN (1) | CN101151030A (OSRAM) |
| AR (1) | AR056291A1 (OSRAM) |
| AU (1) | AU2006228600A1 (OSRAM) |
| BR (1) | BRPI0608656A2 (OSRAM) |
| CA (1) | CA2602563A1 (OSRAM) |
| CL (1) | CL2010000395A1 (OSRAM) |
| EA (1) | EA015122B1 (OSRAM) |
| IL (1) | IL186267A0 (OSRAM) |
| MX (1) | MX2007010664A (OSRAM) |
| NO (1) | NO20074149L (OSRAM) |
| NZ (1) | NZ562775A (OSRAM) |
| TW (1) | TW200722089A (OSRAM) |
| UA (1) | UA92603C2 (OSRAM) |
| WO (1) | WO2006103206A2 (OSRAM) |
| ZA (1) | ZA200706698B (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8906894B1 (en) | 2000-07-27 | 2014-12-09 | Thomas N. Thomas | Methods for preventing and treating thrombotic disorders |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| IL159273A0 (en) * | 2003-12-09 | 2004-06-01 | Transpharma Medical Ltd | Transdermal delivery system for sustained release of polypeptides |
| CA2610757A1 (en) * | 2005-06-10 | 2006-12-14 | Transpharma Medical, Ltd. | Patch for transdermal drug delivery |
| EP2043632A2 (en) * | 2006-07-17 | 2009-04-08 | Boehringer Ingelheim International GmbH | New indications for direct thrombin inhibitors |
| US20100087488A1 (en) * | 2006-10-10 | 2010-04-08 | Boehringer Ingelheim International Gmgh | Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
| DE102006051625A1 (de) | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
| WO2009057112A2 (en) * | 2007-10-29 | 2009-05-07 | Transpharma Medical, Ltd. | Vertical patch drying |
| WO2010013231A2 (en) * | 2008-07-29 | 2010-02-04 | Yeda Research And Development Co. Ltd. | Modulation of coagulation factors and effectors of same for control of transplant organ size |
| EP2323605A4 (en) * | 2008-09-10 | 2014-02-05 | Syneron Medical Ltd | TRANSDERMAL RELEASE OF OLIGOSACCHARIDES |
| TW201031651A (en) * | 2008-11-11 | 2010-09-01 | Boehringer Ingelheim Int | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy |
| AR074313A1 (es) | 2008-11-11 | 2011-01-05 | Boehringer Ingelheim Int | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit |
| CA2738885A1 (en) * | 2008-11-11 | 2010-05-20 | Boehringer Ingelheim International Gmbh | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy |
| EP2384196B1 (en) * | 2008-12-30 | 2017-09-13 | Johansson, Pär | Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof |
| PL2667878T3 (pl) * | 2011-01-25 | 2016-10-31 | Kompozycje i sposoby transplantacji komórek | |
| CN102250099B (zh) * | 2011-05-16 | 2013-10-16 | 中国药科大学 | 一类非肽类抗凝血酶抑制剂、其制法以及医药用途 |
| EP2806879B1 (en) | 2012-01-25 | 2019-03-06 | Université Catholique de Louvain | Compositions and methods for cell transplantation |
| WO2014001220A1 (en) | 2012-06-25 | 2014-01-03 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
| EP2722034B1 (en) * | 2012-10-19 | 2020-09-16 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral pharmaceutical formulations comprising dabigatran |
| EP2722033A1 (en) * | 2012-10-19 | 2014-04-23 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical Compositions of Dabigatran Free Base |
| JP6474394B2 (ja) | 2013-07-05 | 2019-02-27 | ユニベルシテ カトリック ドゥ ルーベン | ヒト成体肝臓幹細胞由来の馴化培地および肝臓障害の治療におけるその使用 |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| CN105250286A (zh) * | 2015-11-13 | 2016-01-20 | 谭惠娟 | 一种抗血栓组合物 |
| CN108236612A (zh) * | 2016-12-27 | 2018-07-03 | 李志忠 | 用于冠脉介入手术中抗凝的组合产品及其用途 |
| WO2020180489A1 (en) * | 2019-03-06 | 2020-09-10 | University Of Rochester | Anticoagulant compositions and uses thereof |
| US11654036B2 (en) | 2020-05-26 | 2023-05-23 | Elixir Medical Corporation | Anticoagulant compounds and methods and devices for their use |
| CN115192691B (zh) * | 2022-08-31 | 2025-03-04 | 晓恩医药包装材料(安庆)有限公司 | 一种阿加曲班注射液及预灌封注射器 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) * | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| US5510330A (en) * | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
| NZ286082A (en) * | 1995-03-15 | 1998-09-24 | Behringwerke Ag | Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment |
| FR2744918B1 (fr) * | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
| PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| US6414008B1 (en) * | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
| DE19834751A1 (de) * | 1998-08-01 | 2000-02-03 | Boehringer Ingelheim Pharma | Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel |
| GB9930540D0 (en) * | 1999-12-23 | 2000-02-16 | Rhone Poulenc Rorer Pharma | Chemical compounds |
| GB0014134D0 (en) * | 2000-06-10 | 2000-08-02 | Astrazeneca Ab | Combination therapy |
| US8183206B2 (en) * | 2001-09-14 | 2012-05-22 | Mitsubishi Tanabe Pharma Corporation | Drugs comprising combination of antithrombotic agent with pyrazolone derivative |
| DK1485094T4 (da) * | 2002-03-07 | 2020-06-22 | Boehringer Ingelheim Int | Doseringsform til oral indgivelse af 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester eller dets salte |
| DE10235639A1 (de) * | 2002-08-02 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel |
| BRPI0409796A (pt) * | 2003-04-24 | 2006-05-30 | Boehringer Ingelheim Int | uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina |
-
2006
- 2006-03-26 US US11/277,503 patent/US20060222640A1/en not_active Abandoned
- 2006-03-27 MX MX2007010664A patent/MX2007010664A/es not_active Application Discontinuation
- 2006-03-27 CA CA002602563A patent/CA2602563A1/en not_active Abandoned
- 2006-03-27 UA UAA200711762A patent/UA92603C2/ru unknown
- 2006-03-27 KR KR1020077024953A patent/KR20070116936A/ko not_active Ceased
- 2006-03-27 CN CNA2006800108359A patent/CN101151030A/zh active Pending
- 2006-03-27 JP JP2008503489A patent/JP2008534552A/ja active Pending
- 2006-03-27 EP EP06725316A patent/EP1885354A2/en not_active Withdrawn
- 2006-03-27 BR BRPI0608656-0A patent/BRPI0608656A2/pt not_active IP Right Cessation
- 2006-03-27 NZ NZ562775A patent/NZ562775A/en unknown
- 2006-03-27 WO PCT/EP2006/061046 patent/WO2006103206A2/en not_active Ceased
- 2006-03-27 EA EA200701841A patent/EA015122B1/ru not_active IP Right Cessation
- 2006-03-27 AU AU2006228600A patent/AU2006228600A1/en not_active Abandoned
- 2006-03-28 TW TW095110732A patent/TW200722089A/zh unknown
- 2006-03-29 AR ARP060101205A patent/AR056291A1/es unknown
-
2007
- 2007-08-10 NO NO20074149A patent/NO20074149L/no not_active Application Discontinuation
- 2007-08-13 ZA ZA200706698A patent/ZA200706698B/xx unknown
- 2007-09-25 IL IL186267A patent/IL186267A0/en unknown
-
2010
- 2010-03-19 US US12/727,933 patent/US20100184729A1/en not_active Abandoned
- 2010-04-21 CL CL2010000395A patent/CL2010000395A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006103206A3 (en) | 2007-01-11 |
| CN101151030A (zh) | 2008-03-26 |
| US20100184729A1 (en) | 2010-07-22 |
| NO20074149L (no) | 2007-12-11 |
| AR056291A1 (es) | 2007-10-03 |
| US20060222640A1 (en) | 2006-10-05 |
| BRPI0608656A2 (pt) | 2010-01-19 |
| CA2602563A1 (en) | 2006-10-05 |
| IL186267A0 (en) | 2008-01-20 |
| TW200722089A (en) | 2007-06-16 |
| JP2008534552A (ja) | 2008-08-28 |
| NZ562775A (en) | 2011-03-31 |
| MX2007010664A (es) | 2007-12-12 |
| AU2006228600A1 (en) | 2006-10-05 |
| WO2006103206A2 (en) | 2006-10-05 |
| EA200701841A1 (ru) | 2008-02-28 |
| EA015122B1 (ru) | 2011-06-30 |
| EP1885354A2 (en) | 2008-02-13 |
| KR20070116936A (ko) | 2007-12-11 |
| UA92603C2 (ru) | 2010-11-25 |
| ZA200706698B (en) | 2008-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2010000395A1 (es) | Composicion farmaceutica que comprende dabigatran, inhibidor directo de la trombina y uno o mas inhibidores de plaquetas seleccionado entre clopidogrel y ticlopidina; y su uso para tratar enfermedades tales como trombosis venosa profunda y embolia pulmonar, entre otros eventos troboticos.8divisional de la solictud 687-06) | |
| EA200900091A1 (ru) | Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний | |
| CR9875A (es) | Inhibidores de dipeptidilo peptidasa para tratar diabetes | |
| NI200700320A (es) | Inhibidores de la actividad akt | |
| EA200901486A1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR | |
| NO20074431L (no) | Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer | |
| ATE464303T1 (de) | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen | |
| ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
| UY32192A (es) | COMPUESTOS PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDA COMO INHIBIDORES DE TRK CINASA | |
| DOP2002000438A (es) | Inhibidores de la dipetidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes | |
| AR073420A1 (es) | Variantes de serina proteasas, composiciones y metodos de limpieza que las comprenden | |
| NO20083202L (no) | ANG2- og VEFG-inhibitorkombinasjoner | |
| NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
| PT1660507E (pt) | Inibidores de proteassoma e seus métodos de utilização | |
| NO20071078L (no) | Antivirale forbindelser | |
| NO20070866L (no) | Antivirale forbindelser. | |
| MX2009013332A (es) | Inhibidores de ire-1 alfa. | |
| HN2009001112A (es) | Inhibidores de la actividad de la akt | |
| CO6761389A2 (es) | Inhibidores de nampt y rock | |
| ECSP067076A (es) | Derivados de pirimidina urea como inhibidores de la quinasa | |
| WO2012135697A3 (en) | Novel rho kinase inhibitors and methods of use | |
| NO20072558L (no) | Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav | |
| DE602005019971D1 (de) | Inhibitoren von cysteinprotease | |
| EA200901484A1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR | |
| ATE456571T1 (de) | Proteasom-hemmer und verwendungsverfahren dafür |